EnovisENOV
Recorded

Enovis Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration24 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Yuan LiAnalyst

All right, why don't we kick this session off? Welcome to the Jefferies Healthcare Conference. My name is Young Li, one of the medtech analysts on the team. Really pleased to be joined by management from Enovis. We have Damien McDonald, CEO, and Ben Berry, CFO. In the audience, we've got Kyle Rose, VP IR. Gentlemen, welcome, and thanks for coming to our conference.

Damien McDonaldCEO

Thanks for having us, Young. Good to see you. All right, great.

Yuan LiAnalyst

I guess to kick off, maybe just macro higher level. Some of your ortho competitors, peers have recently talked about, I guess, some market softness, some of the ortho spine companies as well. Can you maybe talk about what you're seeing out there?

Damien McDonaldCEO

Yeah, look, I think in the last, what, four weeks, all of a sudden it's got pretty noisy about what's going on in the market. For us, I would say this. In terms of a long-term trend, I think orthopedics is really stable. The market dynamic for patient flow ultimately is a tailwind for orthopedics. So I think big macro position, we're in a good place. I would say it's definitely been choppy the last six, nine months. In fact, we were saying in Q1 that we think that the markets have slowed, particularly in Western Europe. That's not just our data. There's pooled industry data that showed that that was what was going on from Q4. We had been seeing that slowdown in Europe, and I think in the last six months, definitively seeing it in the U.S. I can't attribute it to any one thing.

Damien McDonaldCEO

I think it's a confluence of events. I think it's something to do with consumer sentiment, tied to something to do with inflation, tied to something to do with payer scrutiny, which I think is the politically correct way to say it. I think there's something to do with the deductibles and healthcare funding. Put that all in a blender, all of that, I think, is affecting what's going on in the market. As I said, I think the long-term view is patient flow ultimately supports a good orthopedics industry.

Yuan LiAnalyst

Mm-hmm. All right, understood. I guess in early September, you laid out some growth goals for 2027 through 2029 with the announcement of eCential Robotics. We'll get to that in a bit. For next year, you were expecting or are expecting mid-single organic top-line growth, and Recon is supposed to be high single, P&R is supposed to be low single. I guess, what do you have to see from the end market in order to deliver on that result? How de-risked do you think that target or goal is?

Damien McDonaldCEO

Yeah, I think, let me start with P&R. We've been shaping the portfolio to a sort of now 50% of the portfolio is mid-single digit or greater. What I like about the P&R business is it's a very diversified portfolio. No one thing really impacts the entire entity. It's a steady 3%-4% grower and generates a lot of cash. For us, I think P&R is relatively de-risked. What would be to the upside is if Western Europe comes back, and we skew particularly to France and Germany. For us, where we're bound here is with Western Europe. Overall, I like that portfolio, again, because it's so diversified, and the brands are huge in terms of their brand loyalty and stickiness with things like DonJoy and Aircast. I think P&R is relatively de-risked.

Damien McDonaldCEO

To the Recon side of the house, again, I think what we would like to see is Europe stabilize. We've been seeing that the last couple of months, but I'd like to see more stability there. In the U.S., which is an important market for us, obviously, we believe that things are pretty visible in terms of coming back to what I think is a normal. Again, I think we've put out numbers that we think are conservative to be prudent. Anything you want to say about that?

Ben BerryCFO

I think we've consistently delivered that kind of profile over the last many years, and so we expect that to continue.

Yuan LiAnalyst

Mm-hmm. All right, great. I guess sticking to P&R real quick, more than half of the portfolio is growing mid-single digit plus. How high do you think that 50% can get to? How can you continue to reshape the portfolio? Are there any products that you can continue to divest following the Dr. Comfort divestiture?

Damien McDonaldCEO

Yeah, I think, again, we feel very confident about the way this portfolio is growing. The tailwinds, things like the OA portfolio, the NOPAIN Act, and the support for cold therapy have been really important. Importantly, that's talking about the product side of the house. We don't talk as much about the service side of the house, where we've been really able to grow very consistently in terms of the number of accounts, like double-digit account acquisition in terms of who we're supporting with the MotionMD, MotionIQ. We have 99% customer satisfaction, so it's a hugely sticky portfolio. That, for us, is how we're going to continue to shape it. This workflow for us, how do we continue to ratchet this up, is the revenue cycle management and workflow aspect of the clinic is where we see the real opportunity, supported by these strong brands.

Yuan LiAnalyst

All right. Got it. Then maybe shifting gears to Recon a little bit. You've been taking share in that for many years now. I guess more recently, the growth gap versus the market has narrowed, especially as you get bigger. What are some of the, I guess, key Recon products or potential new launches that can enable continued above-market growth over the next few years?

Damien McDonaldCEO

Yeah, I really like the way the team is approaching this. There are two things to this. There is the commercial execution, and then there is the innovation execution. We have had a pretty good run, especially through all of the acquisitions on the innovation execution, bringing portfolios together, and making them compatible across the range. We have, last 7-12 months, really much more focused on the commercial execution. How do we drive customer targeting and segmenting? How do we think about funnel management? That, for us, has really been a useful aspect of what we have brought to the group in the last 7-12 months. You talk about the growth narrowing.

Damien McDonaldCEO

I think one of the pointers of success here, and back to Ben's point about sustainability, the last year-to-date number, I think your model is at 3% for hip and knee, and we are nearly at 6% for hip and knee in the U.S. So, we like the cadence of the way we are executing, and we like the cadence of what we have coming in the portfolio 2027, 2028, in terms of singles and doubles in the pipeline.

Yuan LiAnalyst

Mm-hmm. All right, great. Just on the eCential Robotics deal, why was eCential the right asset to acquire? Why now? How important is having a robot in the portfolio, just based on the conversations that you have been having with surgeons as well as investors?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day